Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | ERN1 | O75460 | 5/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.36 |
| ▸ | MAPT | P10636 | 3/20 | 0.36 |
| ▸ | MEN1 | O00255 | 3/20 | 0.36 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.36 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.36 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.36 |
| ▸ | GSK3B | P49841 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
| ▸ | BLM | P54132 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dimethylformamide SCHEMBL7991275 | 0.91 | LMNA (0.40) | LMNAHPGDERN1ALDH1A1TDP1 | |
| SCHEMBL29914868 | 0.85 | ERN1 (0.40) | LMNAHPGDERN1ALDH1A1TDP1 | |
| SCHEMBL22297792 | 0.85 | ERN1 (0.40) | LMNAHPGDERN1ALDH1A1TDP1 | |
| SCHEMBL8687446 | 0.79 | MEN1 (0.38) | ALDH1A1KMT2AMAPTMEN1PLA2G1B | |
| SCHEMBL12553097 | 0.78 | LMNA (0.46) | LMNAHPGDERN1ALDH1A1TDP1 | |
| SCHEMBL1748269 | 0.78 | ERN1 (0.44) | LMNAHPGDERN1ALDH1A1TDP1 | |
| SCHEMBL30902339 | 0.78 | ERN1 (0.44) | LMNAHPGDERN1ALDH1A1TDP1 | |
| SCHEMBL15828709 | 0.74 | LMNA (0.42) | LMNAHPGDERN1ALDH1A1TDP1 | |
| SCHEMBL7134467 | 0.74 | LMNA (0.54) | LMNAHPGDERN1ALDH1A1TDP1 | |
| SCHEMBL161792 | 0.72 | GSK3B (0.54) | LMNAHPGDERN1ALDH1A1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108727176-B | Method for preparing 5-halogen-2, 3-dihydroxy benzaldehyde | 荆楚理工学院 | 2021-05-18 | — | — | CN | disclosed |
| EP-2064192-B1 | COMPOUNDS AND METHODS FOR INHIBITING THE INTERACTION OF BCL PROTEINS WITH BINDING PARTNERS | INFINITY DISCOVERY INC (US) | 2014-05-14 | — | — | EP | disclosed |
| US-20130131063-A1 | Compounds and Methods for Inhibiting the Interaction of BCL Proteins with Binding Partners | INFINITY PHARMACEUTICALS, INC. (US) | 2013-05-23 | — | — | US | disclosed |
| US-20130131063-A1 | Compounds and Methods for Inhibiting the Interaction of BCL Proteins with Binding Partners | INFINITY PHARMACEUTICALS, INC. (US) | 2013-05-23 | — | — | US | disclosed |
| US-8178690-B2 | Compounds and methods for inhibiting the interaction of BCL proteins with binding partners | INFINITY PHARMACEUTICALS, INC. (US) | 2012-05-15 | — | — | US | disclosed |
| US-8178690-B2 | Compounds and methods for inhibiting the interaction of BCL proteins with binding partners | INFINITY PHARMACEUTICALS, INC. (US) | 2012-05-15 | — | — | US | disclosed |
| US-20110213145-A1 | Compounds and Methods for Inhibiting the Interaction of BCL Proteins with Binding Partners | INFINITY DISCOVERY, INC. (US) | 2011-09-01 | — | — | US | disclosed |
| US-20110213145-A1 | Compounds and Methods for Inhibiting the Interaction of BCL Proteins with Binding Partners | INFINITY DISCOVERY, INC. (US) | 2011-09-01 | — | — | US | disclosed |
| US-7928244-B2 | Isoxazolidine small molecules; cancer, hyperproliferation disorders; blocking antiapoptotic function | INFINITY DISCOVERY, INC. (US) | 2011-04-19 | — | — | US | disclosed |
| US-7928244-B2 | Isoxazolidine small molecules; cancer, hyperproliferation disorders; blocking antiapoptotic function | INFINITY DISCOVERY, INC. (US) | 2011-04-19 | — | — | US | disclosed |
| US-6440962-B2 | CARDIOVASCULAR DISORDERS, ANTIISCHEMIC AGENTS | WARNER-LAMBERT COMPANY | 2002-08-27 | — | — | US | disclosed |
| US-20020094980-A1 | Certain benzothiazine dioxide endothelin antagonists and processes for their preparation | BUNKER AMY MAE (US) | 2002-07-18 | — | — | US | disclosed |
| CN-1326933-A | Process for preparing bromo-ortho-piperonaldehyde | WANG SHIGUO (CN) | 2001-12-19 | — | — | CN | disclosed |
| US-20010036944-A1 | Certain benzothiazine dioxide endothelin antagonists and processes for their preparation | BUNKER AMY MAE (US) | 2001-11-01 | — | — | US | disclosed |
| US-6265399-B1 | ALKYLATION; CYCLIZATION | WARNER-LAMBERT COMPANY | 2001-07-24 | — | — | US | disclosed |
| US-6252070-B1 | REACTING ARYL BROMIDE WITH BUTYLLITHIUM AND ZINC BROMIDE TO GIVE ARYL ZINC BROMIDE; REACTING WITH CORRESPONDING BENZOTHIAZINE COMPOUND | WARNER-LAMBERT COMPANY | 2001-06-26 | — | — | US | disclosed |
| EP-1009743-A1 | CERTAIN BENZOTHIAZINE DIOXIDE ENDOTHELIN ANTAGONISTS AND PROCESSES FOR THEIR PREPARATION | WARNER-LAMBERT COMPANY (US) | 2000-06-21 | — | — | EP | disclosed |
| WO-1999012916-A1 | CERTAIN BENZOTHIAZINE DIOXIDE ENDOTHELIN ANTAGONISTS AND PROCESSES FOR THEIR PREPARATION | WARNER-LAMBERT COMPANY (US) | 1999-03-18 | — | — | WO | disclosed |
| US-5807860-A | ACYLCOENZYME A:CHOLESTEROL ACYLTRANSFERASE INHIBITORS; HYPERLIPEMIA, ATHEROSCLEROSIS; ANTICHOLESTEROL AGENTS | MITSUBISHI CHEMICAL CORPORATION (JP) | 1998-09-15 | — | — | US | disclosed |
| EP-0773218-A1 | N-(Piperazinylalkoxyphenyl)-N'phenylalkylurea derivatives as ACAT inhibitors for the treatment of atheroschlerosis | MITSUBISHI CHEMICAL CORPORATION (JP) | 1997-05-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110213145-A1 | Compounds and Methods for Inhibiting the Interaction of BCL Proteins with Binding Partners | BCL2, BCL2L1, BCL2L11 | LMNA 3721/4885HPGD 2241/4885ERN1 2926/4885 |
| US-20020094980-A1 | Certain benzothiazine dioxide endothelin antagonists and processes for their preparation | ECE1, EDNRA, EDNRB | LMNA 2078/4885HPGD 1103/4885ERN1 1288/4885 |
| US-20010036944-A1 | Certain benzothiazine dioxide endothelin antagonists and processes for their preparation | ECE1, EDNRA, EDNRB | LMNA 2078/4885HPGD 1103/4885ERN1 1288/4885 |
| US-20130131063-A1 | Compounds and Methods for Inhibiting the Interaction of BCL Proteins with Binding Partners | BCL2, BCL2L1, BCL2L11 | LMNA 3721/4885HPGD 2241/4885ERN1 2926/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.